The study of the new regimen of the AZT administration to the neonate for preventing HIV mother-to-child transmission

The study of the new regimen of the AZT administration to the neonate for preventing HIV mother-to-child transmission - Comparative analysis of the effectiveness and safety between two regimens;AZT for 6 weeks(previous regimen) and AZT for 4 weeks(new regimen)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015270

Enrollment

Registered

2014-09-27

Start date

2014-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Interventions

The neonates are given 4mg/kg of AZT twice a day for 4 weeks orally/intravenously

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The neonates who are born by HIV positive mothers in National Center for Global Health and Medicine(NCGM) 2)The neonates whose informed consent is obtained from HIV positive mothers

Exclusion criteria

Exclusion criteria: The neonates whose informed consent is not obtained from HIV positive mothers

Design outcomes

Primary

Measure	Time frame
1)HIV mother-to-child transmission: HIV antibody detection at one and half year of age 2)The degree of born marrow suppression:The minimum values of hemoglobin,white blood cells,neutrophile counts,platelets at 0 to 1 day of age and 2 to 4 months of age	—

Countries

Japan

Contacts

Public ContactMizue Tanaka

National Center for Global Health and Medicine Department of Pediatrics

mitanaka@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026